Drug Development Consulting

You can rely on our regulatory intelligence as well as on the experience and expertise of our consultants for the success of your project.


BlueReg can provide you with an end-to-end project plan to guide you from the development of your product right through to authorization and beyond.


The services we offer include:


  • Due diligence for licensing or investment decision making
  • Strategic expert input and regulatory advice (Chemistry Manufacturing and Controls, non-clinical, clinical, efficacy and safety)
  • Data assessment, interpretation and positioning
  • Advice on global development plans (including Integration of value based pay evidence requirements), global regulatory strategy and meetings with regulators or payers
  • Scientific writing of regulatory documents (EU and US): Briefing
    documents for scientific advice, Orphan Drug Designation (ODD),
    Pediatric Investigation Plan (PIP), Investigational Medicinal Product Dossier (IMPD) and Investigational New Drug (IND), Clinical study reports, Marketing Authorization Application (MAA) and New Drug Application (NDA) / Biologics License Application (BLA) modules and Responses To agency Questions (RTQ)
  • Scientific writing of Pharmacovigilance / safety documents: Risk Management Plan (RMP), Development Safety Update Reports (DSURs) and Periodic Benefit Risk Evaluation Reports (PBRERs)
  • Operational support and regulatory project management for ODD, PIP,
    scientific advice, IMPD, IND, Clinical Trial Applications (CTAs), Case Study Reports (CSRs), Development Safety Update Reports (DSURs) including regulatory publishing
  • Development of Client-Customized Operational Platforms

Drug Development Strategy

The Consultants in our Global Regulatory Services team have extensive European Medicines Agency (EMA), Food and Drug Administration (FDA) and national Regulatory Agency experience. They can provide advice and recommendations to ensure the shortest time to market by minimising any possible barriers.


Our experts can help you understand new and existing guidance to ensure the medicinal product meets all regulatory guidelines; and support with product development strategy from early phase to the marketing authorisation submission.




BlueReg can also define effective regulatory strategies, aligned with the company’s and regulatory requirements, in order to facilitate post approval activities. Submissions can be prepared, or reviewed for deficiencies, along with a thorough gap analysis and risk assessment prior to submission to ensure that any questions that may arise from Health Authorities are anticipated and can be prepared for responses.


BlueReg can also help with Quality Control and publishing of regulatory submissions, and preparation for Agency meetings.


Our experts

Associated Resources

Define & implement the European Health Authorities consultation strategy for a US-based client

BlueReg made recommendations to a US based client on which Health Authorities in the European...

Learn more

Support for a Paediatric Investigation Plan in the European Union, for a US-based client

Read our latest PIP case study following our recent webinar!   Discover how BlueReg provided...

Learn more

Support for CHMP Scientific Advice

Two global companies recently entrusted to BlueReg the management of a Committee for Medicinal Products...

Learn more